 Connection
Sharon Pine to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Sharon Pine has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.538 |
|
|
|
-
Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021 12 31; 42(12):1411-1419.
Score: 0.145
-
Epsi NJ, Panja S, Pine SR, Mitrofanova A. pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma. Commun Biol. 2019; 2:334.
Score: 0.123
-
Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML, White E, Rodriguez-Rodriguez L, Mehnert JM, Ganesan S. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. Clin Cancer Res. 2017 Sep 15; 23(18):5631-5638.
Score: 0.105
-
Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013 Jul; 34(7):1420-30.
Score: 0.079
-
Pine SR, Marshall B, Varticovski L. Lung cancer stem cells. Dis Markers. 2008; 24(4-5):257-66.
Score: 0.055
-
Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, Ganesan S. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. J Thorac Oncol. 2019 11; 14(11):1982-1988.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|